CN106214844A - A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof - Google Patents
A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof Download PDFInfo
- Publication number
- CN106214844A CN106214844A CN201610729488.0A CN201610729488A CN106214844A CN 106214844 A CN106214844 A CN 106214844A CN 201610729488 A CN201610729488 A CN 201610729488A CN 106214844 A CN106214844 A CN 106214844A
- Authority
- CN
- China
- Prior art keywords
- parts
- compositions
- fat
- reducing
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 230000000694 effects Effects 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 230000007365 immunoregulation Effects 0.000 title claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 39
- 241000756943 Codonopsis Species 0.000 claims abstract description 32
- 241000222336 Ganoderma Species 0.000 claims abstract description 31
- 239000009636 Huang Qi Substances 0.000 claims abstract description 31
- 241000208340 Araliaceae Species 0.000 claims abstract description 30
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 29
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 29
- 235000008434 ginseng Nutrition 0.000 claims abstract description 29
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 32
- 239000008187 granular material Substances 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000007779 soft material Substances 0.000 claims description 14
- 239000004375 Dextrin Substances 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 12
- 235000019425 dextrin Nutrition 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims 1
- 235000011613 Pinus brutia Nutrition 0.000 claims 1
- 241000018646 Pinus brutia Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 16
- 241001465754 Metazoa Species 0.000 abstract description 9
- 230000037396 body weight Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 239000000725 suspension Substances 0.000 description 12
- 238000003304 gavage Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 9
- 230000000242 pagocytic effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 208000033065 inborn errors of immunity Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 235000011609 Pinus massoniana Nutrition 0.000 description 1
- 241000018650 Pinus massoniana Species 0.000 description 1
- 235000011610 Pinus tabuliformis Nutrition 0.000 description 1
- 241000018651 Pinus tabuliformis Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037205 Sal-like protein 2 Human genes 0.000 description 1
- 101710192308 Sal-like protein 2 Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000012826 global research Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000008492 tangshen Substances 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000009891 weiqi Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The invention provides a kind of compositions with fat-reducing and immunoregulation effect, by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma, Radix Ginseng, Pollen Pini according to certain weight proportion, add pharmaceutically acceptable adjuvant, extract formulated preparation according to certain preparation method.Animal experiment shows, application above-mentioned composition can effectively reduce body weight, reduce fat mass, improves immunity of organisms.Said composition raw material selection refine, reasonable recipe, preparation method is easy, safely and effectively.
Description
Technical field
The present invention relates to medicine and field of health care food, particularly relate to a kind of combination with fat-reducing and immunoregulation effect
Thing and preparation method thereof.
Background technology
Immunity is that human body is resisted extraneous virulence factor and maintains the ability of homoiostasis, namely human immunity system
System carries out a kind of ability of self-protection.The main task of immunity is resistant to the infection of antibacterial or virus etc., maintains life
Normal growth is grown and healthy.Immune system is made can not normally to play the reason of protective effect varied.Along with people live
The quickening of rhythm and the enhancing of operating pressure, psychological unbalance, hypotrophy, life do not have rule, take exercise inadequate, abuse medicine
Etc., all can cause hypoimmunity.Hypoimmunity, can directly affect the healthy of people, causes making a difference daily
Life, the body obstacle of working and learning.
Fat and hypoimmunity is closely related.Canada's up-to-date global research of McMaster University one is sent out
Existing, obesity becomes people and has an aptitude to a big New risk factors of influenza.Further, than general patient's after overweight people infects influenza
Mortality rate exceeds nearly 3 times.There are some researches show, when influenza attacks, the high-risk group really of overweight people.Therefore, preventing and treating obesity, increase
Strong immunity of organisms, safeguards healthy most important.
Immunoregulation medicament is also referred to as immunostimulant, clinical its immunological enhancement of mainly using, treatment immunodeficiency disease
Disease, chronic infection and the auxiliary as tumor are treated.Common medicine have levamisole, interleukin, interferon, transfer because of
Son, thymosin etc..The immunoreation of human body is an extremely complex process, affected by various factors and restriction.This kind of
The medicament for immunity enhancement mechanism of action is single, generally requires when treatment and comprehensively adjusts immunity.And be not provided simultaneously with
Strengthen the medicine of immunity and antiobesity action.
In traditional medicine, early there is immunologic concept."Nei Jing" is mentioned " vital QI in the body flowing normally, keeping a sound mind, sick peace from
Come ", the viewpoint such as " healthy energy deposit in, heresy can not be done "." healthy energy " is typically for pathogenic factor (all virulence factors), also known as
" vital qi ", refers to the ability of human body resist the disease, the most also includes the immunity of human body.Modern Chinese medicine think disease generation, send out
Opening up and lapse to depend on the growth and decline of good and evil, obesity, hypoimmunity are all closely related with positive QI-insufficiency, thus propose " righting
Eliminating evil " principle of mainly curing the disease.Chinese medicine mostly is natural drug, and the property of medicine is gentle, and untoward reaction is few, in blood fat reducing loss of weight and enhancing body
Immunity aspect has the drug effect of uniqueness.By this kind of Chinese medicine under the guidance of theory of Chinese medical science, carry out prescription compatibility, play Chinese medicine and join
Side's multicomponent, Mutiple Targets, multipath and integrally-regulated feature, carry out immunomodulating to human body, become people in the art
Member's problem demanding prompt solution.
Summary of the invention
For above-mentioned situation, the present invention will provide a kind of compositions with fat-reducing and immunoregulation effect, said composition
Compatibility is proper, effectively reduces body weight, reduces fat mass, improves immunity of organisms.
It is a further object to provide the preparation method of a kind of compositions with fat-reducing and immunoregulation effect.
It is a still further object of the present invention to provide said composition at preparation fat-reducing and the food of immunoregulation effect, health product
Or the purposes in medicine.
Heretofore described a kind of compositions with fat-reducing and immunoregulation effect, raw material and the weight of said composition are joined
Ratio is: the Radix Astragali 10～30 parts, Fructus Lycii 9～25 parts, Radix Codonopsis 10～20 parts, Ganoderma 9～16 parts, Radix Ginseng 5～15 parts, Pollen Pini 1
～5 parts.
Preferably, described a kind of compositions with fat-reducing and immunoregulation effect, raw material and the weight of said composition are joined
Ratio is: the Radix Astragali 12～25 parts, Fructus Lycii 11～20 parts, Radix Codonopsis 13～18 parts, Ganoderma 11～14 parts, Radix Ginseng 7～12 parts, Pollen Pini
3～5 parts.
A kind of there is fat-reducing and the compositions of immunoregulation effect it is further preferred that described, the raw material of said composition and
Weight proportion is: the Radix Astragali 20 parts, Fructus Lycii 18 parts, Radix Codonopsis 15 parts, Ganoderma 12 parts, Radix Ginseng 10 parts, Pollen Pini 3 parts.
The present composition is to use above-mentioned raw materials medicine, adds pharmaceutically acceptable adjuvant, conventionally, preparation
Preparation.
Preferably, described preparation is extracted be prepared as extracting by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma, Radix Ginseng conventional method
Thing, Pollen Pini is directly used as medicine and makes.
It is further preferred that described extract is decocting thing, described preparation is oral formulations.
It is further preferred that described oral formulations is granule, tablet, capsule, mixture.
Present invention also offers the preparation method of said composition, comprise the steps:
(1) raw material is weighed by weight.
(2) Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma and people are participated in the water heating extraction at least 2 times of at least 10 times amount, every time
Extraction time is at least 2 hours, united extraction liquid, filters, obtains filtrate；
(3) step (2) gained filtrate is condensed into thick paste；
(4) step (3) gained thick paste is dried to obtain dry extract；
(5) step (4) gained dry extract is pulverized and sieved, obtain dry extract；
(6) Pollen Pini is sieved, obtain Pollen Pini fine powder；
(7) dextrin of step (5) gained dry extract amount 0.8～1.5 times amount is weighed, with described dry extract, step (6)
Gained Pollen Pini fine powder mix homogeneously；Adding appropriate 85% ethanol is wetting agent soft material；
(8) step (7) gained soft material is sieved granulation, obtain wet granular, wet grain drying, granulate, packaging, obtain granule
Agent.
Present invention also offers said composition in preparation fat-reducing and the food of immunoregulation effect, health product or medicine
Purposes.
The Radix Astragali being previously mentioned in the present invention is that the dry root of leguminous plant Radix Astagali or Radix Astragali processes from strand, i.e.
The Radix Astragali that " Chinese Pharmacopoeia " (version in 2015) is recorded.
The Fructus Lycii being previously mentioned in the present invention is that the dry mature fruit of plant of Solanaceae lycium barbarum processes from strand, i.e.
The Fructus Lycii that " Chinese Pharmacopoeia " (version in 2015) is recorded.
The Radix Codonopsis being previously mentioned in the present invention be Campanulaceae Radix Codonopsis, element flower Radix Codonopsis or the dry root of radix codonpsis tangshen processed and
Become, the Radix Codonopsis that i.e. " Chinese Pharmacopoeia " (version in 2015) is recorded.
The Ganoderma being previously mentioned in the present invention processes from strand for the dry sporophore of On Polyporaceae Ganoderma lucidum (Leyss. Ex Fr.) Karst. or Ganoderma,
The Ganoderma that i.e. " Chinese Pharmacopoeia " (version in 2015) is recorded.
The Radix Ginseng being previously mentioned in the present invention is the dry root of Araliaceae Radix Ginseng and rhizome processes from strand, i.e. " China
Pharmacopeia " (version in 2015) Radix Ginseng of recording.
The Pollen Pini being previously mentioned in the present invention is pinaceae plant Pinus massoniana Lamb, Pinus tabuliformis or the dry pollen warp belonging to several plants together
Process, the Pollen Pini that i.e. " Chinese Pharmacopoeia " (version in 2015) is recorded.
The pharmaceutically acceptable adjuvant being previously mentioned in the present invention, including " medicinal excipient handbook " (American Pharmaceutical Association,
In October, 1986), Chemical Industry Press publish " pharmaceutic adjuvant handbook " (Handbook of Pharmaceutical
Excipients, original work fourth edition) or " pharmaceutical necessities is complete works of " (Sichuan Publishing Group, Sichuan science tech publishing house publish,
In January, 2006) listed by adjuvant, but be not limited to these adjuvants.
Compared with prior art, the method have the advantages that
(1) the choice of drug Radix Astragali of the present invention, Fructus Lycii, Radix Codonopsis, Ganoderma, Radix Ginseng, Pollen Pini are as crude drug, pass through science
Prescription, by certain weight proportion composition.Prove there is blood fat reducing loss of weight, strengthen immune effect through animal experiment.
(2) medication of the present invention is exquisite, and compatibility is proper, and all medicines close medicine, can effectively treat hypoimmunity.Raw material of the present invention
In, the Radix Astragali returns lung, spleen channel, and function focuses on QI invigorating and admittedly holds in the palm, replenishing QI to invigorate the spleen；Fructus Lycii returns liver, kidney channel, function tonification Liver and kidney, benefit essence
Improving eyesight；Radix Codonopsis returns spleen, lung meridian, QI invigorating, promotes the production of body fluid, and nourishes blood；Ganoderma GUIXIN, liver, kidney, lung meridian, invigorating QI and tranquilization, big tonifying the lung is cloudy, defends gas
The ability resisting pathogenic factor rely on a surname's amount of having an effect of lung qi, then to defend gas strong for lung yin foot；Radix Ginseng GUIXIN, spleen, lung meridian, strongly invigorating primordial QI,
Spleen reinforcing the liver benefiting, promotes the production of body fluid, and calms the nerves；Pollen Pini convergence QI invigorating.We with Pollen Pini as monarch drug, main profit cardiopulmonary, take its convergence QI invigorating it
Effect, with the Radix Astragali, Radix Ginseng as ministerial drug, plays effect of QI invigorating, spleen invigorating altogether, and assistant is with Fructus Lycii nourishing the liver and kidney, Radix Codonopsis supplementing QI for promoting the production of body fluid, Ganoderma
Invigorating QI and tranquilization.Full side formula complements each other, treatment Weiqi deficiency caused by disorder of defensive QI, and transporting is unable, thus reach fat-reducing and
The function of enhancing immunity.
(3) crude drug of the present invention is the medical material of medicine-food two-purpose, has long-term edible history, and safety is good.
(4) crude drug of the present invention is conventional Chinese medicine, it is easy to obtaining genuine medicinal materials, raw material sources are stable, matter
Measure easily controllable.
(5) the Pollen Pini un-extracted in the present invention, is directly used as medicine with full powder, remains effective ingredient to greatest extent, subtracts
Having lacked dosage, Pollen Pini is used as medicine with powder simultaneously, decreases the consumption of adjuvant.The present invention uses scientific and rational preparation
Method, prepares safely and effectively preparation so that the effect of regulation immunity of organisms is more stable, controlled.
(6) present invention employs oral formulations, conveniently produce, store, transport, carry and take.
Accompanying drawing explanation
Fig. 1 is granule production technological process.
Detailed description of the invention
Embodiment 1
Composition: Radix Astragali 200g, Fructus Lycii 180g, Radix Codonopsis 150g, Ganoderma 120g, Radix Ginseng 100g, Pollen Pini 30g, dextrin
20g。
Preparation method: weigh the supplementary material of formula ratio, by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma and Radix Ginseng heating extraction 2 times,
Add the water of its formula ratio 10 times amount every time, extract 2 hours every time.Extracting solution merges filtration, and filtrate is concentrated into relative density and is
The thick paste of 1.25～1.30 (60 DEG C of heat are surveyed), is dried to obtain dry extract then at 60 DEG C, dry extract was pulverized 80 mesh sieves, obtains dry extract
Fine powder.By Pollen Pini and dextrin, after crossing 80 mesh sieves respectively, mixing homogeneously with dry extract fine powder, it is wet for adding appropriate 85% ethanol
Moistening agent soft material, soft material is crossed 20 mesh sieves and is pelletized, and obtains wet granular, and wet granular is dried in 60 DEG C, granulate, and packaging obtains granule.
Embodiment 2
Composition: Radix Astragali 110g, Fructus Lycii 120g, Radix Codonopsis 180g, Ganoderma 150g, Radix Ginseng 150g, Pollen Pini 50g, dextrin
25g。
Preparation method: weigh the supplementary material of formula ratio, by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma and Radix Ginseng heating extraction 2 times,
Add the water of its formula ratio 12 times amount every time, extract 2 hours every time.Extracting solution merges filtration, and filtrate is concentrated into relative density and is
The thick paste of 1.25～1.30 (60 DEG C of heat are surveyed), is dried to obtain dry extract then at 60 DEG C, dry extract was pulverized 80 mesh sieves, obtains dry extract
Fine powder.By Pollen Pini and dextrin, after crossing 80 mesh sieves respectively, mixing homogeneously with dry extract fine powder, it is wet for adding appropriate 85% ethanol
Moistening agent soft material, soft material is crossed 20 mesh sieves and is pelletized, and obtains wet granular, and wet granular is dried in 60 DEG C, granulate, and packaging obtains granule.
Embodiment 3
Composition: Radix Astragali 240g, Fructus Lycii 230g, Radix Codonopsis 130g, Ganoderma 120g, Radix Ginseng 80g, Pollen Pini 30g, dextrin 20g.
Preparation method: weigh the supplementary material of formula ratio, by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma and Radix Ginseng heating extraction 3 times,
Add the water of its formula ratio 10 times amount every time, extract 2 hours every time.Extracting solution merges filtration, and filtrate is concentrated into relative density and is
The thick paste of 1.25～1.30 (60 DEG C of heat are surveyed), is dried to obtain dry extract then at 60 DEG C, dry extract was pulverized 80 mesh sieves, obtains dry extract
Fine powder.By Pollen Pini and dextrin, after crossing 80 mesh sieves respectively, mixing homogeneously with dry extract fine powder, it is wet for adding appropriate 85% ethanol
Moistening agent soft material, soft material is crossed 20 mesh sieves and is pelletized, and obtains wet granular, and wet granular is dried in 60 DEG C, granulate, and packaging obtains granule.
Embodiment 4
Composition: Radix Astragali 100g, Fructus Lycii 150g, Radix Codonopsis 170g, Ganoderma 110g, Radix Ginseng 50g, Pollen Pini 10g, dextrin 35g.
Preparation method: weigh the supplementary material of formula ratio, by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma and Radix Ginseng heating extraction 2 times,
Add the water of its formula ratio 12 times amount every time, extract 3 hours every time.Extracting solution merges filtration, and filtrate is concentrated into relative density and is
The thick paste of 1.25～1.30 (60 DEG C of heat are surveyed), is dried to obtain dry extract then at 60 DEG C, dry extract was pulverized 80 mesh sieves, obtains dry extract
Fine powder.By Pollen Pini and dextrin, after crossing 80 mesh sieves respectively, mixing homogeneously with dry extract fine powder, it is wet for adding appropriate 85% ethanol
Moistening agent soft material, soft material is crossed 20 mesh sieves and is pelletized, and obtains wet granular, and wet granular is dried in 60 DEG C, granulate, and packaging obtains granule.
Embodiment 5
Composition: Radix Astragali 280g, Fructus Lycii 90g, Radix Codonopsis 110g, Ganoderma 90g, Radix Ginseng 60g, Pollen Pini 20g, DEXTRIN g.
Preparation method: weigh the supplementary material of formula ratio, by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma and Radix Ginseng heating extraction 2 times,
Add the water of its formula ratio 10 times amount every time, extract 3 hours every time.Extracting solution merges filtration, and filtrate is concentrated into relative density and is
The thick paste of 1.25～1.30 (60 DEG C of heat are surveyed), is dried to obtain dry extract then at 60 DEG C, dry extract was pulverized 80 mesh sieves, obtains dry extract
Fine powder.By Pollen Pini and dextrin, after crossing 80 mesh sieves respectively, mixing homogeneously with dry extract fine powder, it is wet for adding appropriate 85% ethanol
Moistening agent soft material, soft material is crossed 20 mesh sieves and is pelletized, and obtains wet granular, and wet granular is dried in 60 DEG C, granulate, and packaging obtains granule.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all essences in the present invention
Any amendment, equivalent and the improvement etc. made within god and principle, should be included within the scope of the present invention.
The Pharmacodynamics experiment carrying out the present invention and result are as follows:
One, enhancing immunity experiment
(1) by reagent
Invention formulation 1: be prepared into granule by embodiment 1, add water and make suspension.
Invention formulation 2: be prepared into granule by embodiment 2, add water and make suspension.
Invention formulation 3: be prepared into granule by embodiment 3, add water and make suspension.
Invention formulation 4: be prepared into granule by embodiment 4, add water and make suspension.
Invention formulation 5: be prepared into granule by embodiment 5, add water and make suspension.
Negative control: distilled water.
(2) experimental animal: Female ICR mice, body weight 18-22g, by institute of lab animals of Sichuan Academy of Medical Sciences
There is provided.
(3) test data uses SPSS 10.0for Windows software kit to process.Matched group and the data warp of dosage group
Homogeneity test of variance, variance is neat, carries out variance analysis, if P value is less than 0.05, then compares two-by-two by Dunnett method；If side
Difference is uneven, then carry out data conversion, the most uneven, uses rank test instead, if P value is less than 0.05, then enters by Dunnett's T3 method
Row compares two-by-two.
(4) test method and result
1, the impact on mouse cell immunologic function
1.1 impacts on mice delayed allergy (DTH)
1.1.1 test method: delayed allergy (DTH) (ear swelling method)
After gavage 30 days, losing hair or feathers to mouse part skin, about 3cm × 3cm, by DNFB solution 50 μ l uniform application sensitization.5
After it, it is applied in mouse right ear (two sides) with DNFB solution 10 μ l and attacks.Attack latter 24 hours and put to death mice, cut left and right
Auricular concha, takes off the auricle of diameter 8mm, weighs with card punch.
1.1.2 result of the test, is shown in Table 1.
The table 1 impact on mice delayed allergy (DTH)
From table 1, continuous gavage is after 30 days, the ear swelling of invention formulation 1～5 treated animal and negative control group
Compare and more all have significant difference (P < 0.05).
1.2 impacts on the mouse lymphocyte conversion test of ConA induction
The mouse lymphocyte conversion test (mtt assay) of 1.2.1 test method: ConA induction
First the preparation of splenocyte suspension is carried out.Cell concentration is adjusted to 3 × 106Individual/ml, then divides cell suspension
Holes adds in 24 well culture plates, every hole 1ml, and a hole adds 75 μ lConA liquid, and another hole compares, and puts 5%CO2Incubator 37 DEG C training
Support 68h.Cultivation terminates front 4h, every hole gentle aspiration supernatant 0.7ml, adds the 0.7ml RPMI1640 training without calf serum
Nutrient solution, is simultaneously introduced MTT (5mh/ml) 50 μ l/ hole and continues to cultivate 4h, cultivate after terminating, and every hole adds 1ml acid isopropyl alcohol, makes
Purple crystal is completely dissolved, and then moves in cuvette by liquid, with 723 spectrophotometers in 570nm wavelength sheet colorimetric determination
Optical density value.
1.2.2 result of the test, is shown in Table 2.
The table 2 impact on the mouse lymphocyte conversion test that ConA induces
From table 2, continuous gavage is after 30 days, and the lymphopoiesis ability of invention formulation 1～5 treated animal is with negative
Matched group is compared more all significant difference (P < 0.05).
1.3 conclusion
Being shown by the result of table 1, table 2, the test for celluar immunity result of mice is positive by the present invention.
2, the impact on mouse monokaryon-macrophage phagocytic function
2.1 impacts on mouse macrophage phagocytosis chicken red blood cell ability
2.1.1 test method: Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell test (half intracorporal method)
Gavage is after 30 days continuously, and every mouse peritoneal injects 20% chicken erythrocyte suspension 1ml, after 30 points of kinds, and cervical dislocation
Putting to death, be fixed on Mus plate, abdominal skin is cut off in center, through abdominal cavity saline injection 2ml, rotates Mus plate 1 minute, inhales
Going out abdominal cavity washing liquid 1ml, mean droplet, on 2 microscope slides, puts 37 DEG C of wet box 30 minutes, takes out and rinse at normal saline, dries, consolidates
Fixed, 4%GiemsaPBS dyes 3 minutes, distilled water rinsing airing, microscopy.Calculate phagocytic percentage and phagocytic index.
2.1.2 result of the test: be shown in Table 3.
The table 3 impact on mouse macrophage phagocytosis chicken red blood cell ability
From table 3, continuous gavage is after 30 days, and phagocytic rate and the phagocytic index of invention formulation 1～5 treated animal are the most obvious
Raise, compared with negative control group, invention formulation 1～the phagocytic rate of 5 groups and phagocytic index have significant difference (P <
0.05)。
2.2 impacts on mouse monokaryon-macrophage carbonic clearance function
2.2.1 test method: mice carbonic clearance is tested
Gavage is after 30 days continuously, in the mouse tail vein injection india ink of 4 times of normal saline dilutions, by 0.1ml/
10g prepared Chinese ink inject after timing immediately, in injecting after prepared Chinese ink the 2nd, 10min takes blood 20 μ l respectively at angular vein, is added to 2ml
Na2CO3Solution makees blank, measures optical density value with 723 spectrophotometers at 600nm.Take sacrifice after blood, take
Liver, spleen are weighed, and calculate phagocytic index.
The table 4 impact on mouse monokaryon-macrophage carbonic clearance function
From table 4, continuous gavage is after 30 days, the carbonic clearance ability of invention formulation 1～5 treated animal and negative control group
Compare and more all have significant difference (P < 0.05).
2.3 conclusion
Being shown by the result of table 3, table 4, the present invention is sun to the monocytes/macrophages phagocytic function test result of mice
Property.
To sum up, mouse cell immunity test result is positive by the present invention, and the monocytes/macrophages of mice is swallowed merit
Can result of the test be positive.The present invention has the effect of enhancing immunity.
Two, antiobesity action experiment
(1) by reagent:
Invention formulation 1: be prepared into granule by embodiment 1, add water and make suspension.
Invention formulation 2: be prepared into granule by embodiment 2, add water and make suspension.
Invention formulation 3: be prepared into granule by embodiment 3, add water and make suspension.
Invention formulation 4: be prepared into granule by embodiment 4, add water and make suspension.
Invention formulation 5: be prepared into granule by embodiment 5, add water and make suspension.
Negative control: normal saline.
(2) experimental animal: male Wistar rat, body weight about 220 ± 10g, dynamic by Sichuan Academy of Medical Sciences's experiment
Thing institute provides.
(3) test data uses SPSS 10.0for Windows software kit to process.Matched group and the data warp of dosage group
Homogeneity test of variance, variance is neat, carries out variance analysis, if P value is less than 0.05, then compares two-by-two by Dunnett method；If side
Difference is uneven, then carry out data conversion, the most uneven, uses rank test instead, if P value is less than 0.05, then enters by Dunnett's T3 method
Row compares two-by-two.
(4) test method and result
1. set up Diet-induced obesity rat model:
Feeding rat 45 days with nutrient fodder, compared with the rat of the same age of standard full price Mus forage feed, body weight increases, and has
Significant difference.Nutrient fodder is standard full price Mus feedstuff 60%, Adeps Sus domestica 10%, sucrose 6%, milk powder 6%, Semen arachidis hypogaeae 5%, egg
10%, Oleum Sesami 1%, Sal 2%.
2. feed 30 days continuously, routine weighing, record food ration.Experiment terminates, and weighs, and puts to death rat, takes item under omoplate
Rear fat (brown fat) is weighed；Take kidney week Abdominal Wall Fat and epididymal adipose tissues (white adipose), represent internal fat with both sums
Fat amount.
3. result of the test shows, continuous gavage is after 30 days, invention formulation 1～5 treated animal food ration with to negative control
Group is without significant difference.The impact of rat body weight and fat mass is shown in Table 5, table 6.
The table 5 impact on rat body weight
From table 5, continuous gavage is after 30 days, and invention formulation 1～5 treated animal body weight substantially reduces, with negative control
Group compares, and has significant difference (P < 0.05).
The table 6 impact on rat fat amount
From table 6, continuous gavage is after 30 days, and invention formulation 1～5 treated animal fat mass is compared with negative control group
Relatively, there is significant difference (P < 0.05).
4. conclusion
Being shown by the result of table 5, table 6, the fat-reducing result of the test of rat is positive by the present invention.
To sum up, raw material and the weight proportion of the present composition is: the Radix Astragali 10～30 parts, Fructus Lycii 9～25 parts, Radix Codonopsis 10
～20 parts, Ganoderma 9～16 parts, Radix Ginseng 5～15 parts, Pollen Pini 1～5 parts, preferred feedstock and weight proportion be the Radix Astragali 12～25 parts,
Fructus Lycii 11～20 parts, Radix Codonopsis 13～18 parts, Ganoderma 11～14 parts, Radix Ginseng 7～12 parts, Pollen Pini 3～5 parts, further preferably
Raw material and weight proportion are the Radix Astragali 20 parts, Fructus Lycii 18 parts, Radix Codonopsis 15 parts, Ganoderma 12 parts, Radix Ginseng 10 parts, Pollen Pini 3 parts.Application
The compositions that the present invention provides is respectively provided with fat-reducing and immunoregulatory effect.
Claims (10)
1. a compositions with fat-reducing and immunoregulation effect, it is characterised in that: raw material and the weight of described compositions are joined
Ratio is: the Radix Astragali 10 ~ 30 parts, Fructus Lycii 9 ~ 25 parts, Radix Codonopsis 10 ~ 20 parts, Ganoderma 9 ~ 16 parts, Radix Ginseng 5 ~ 15 parts, Pollen Pini 1 ~ 5 part.
A kind of compositions with fat-reducing and immunoregulation effect the most according to claim 1, it is characterised in that: described group
The raw material of compound and weight proportion be: the Radix Astragali 12 ~ 25 parts, Fructus Lycii 11 ~ 20 parts, Radix Codonopsis 13 ~ 18 parts, Ganoderma 11 ~ 14 parts, Radix Ginseng
7 ~ 12 parts, Pollen Pini 3 ~ 5 parts.
A kind of compositions with fat-reducing and immunoregulation effect the most according to claim 1 and 2, it is characterised in that: institute
Raw material and the weight proportion of stating compositions be: the Radix Astragali 20 parts, Fructus Lycii 18 parts, Radix Codonopsis 15 parts, Ganoderma 12 parts, Radix Ginseng 10 parts, pine
Pollen 3 parts.
4., according to a kind of compositions with fat-reducing and immunoregulation effect described in any one of claim 1 ~ 3, its feature exists
In: described compositions is with the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma, Radix Ginseng, Pollen Pini as crude drug, adds pharmaceutically acceptable
The preparation that adjuvant is conventionally prepared from.
A kind of compositions with fat-reducing and immunoregulation effect the most according to claim 4, it is characterised in that: described system
Agent is extracted be prepared as extract by the Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma, Radix Ginseng conventional method, and Pollen Pini is directly used as medicine and makes.
A kind of compositions with fat-reducing and immunoregulation effect the most according to claim 5, it is characterised in that carry described in:
Taking thing is decocting thing.
7. according to a kind of compositions with fat-reducing and immunoregulation effect described in claim 4 or 5, it is characterised in that: institute
Stating preparation is oral formulations.
A kind of compositions with fat-reducing and immunoregulation effect the most according to claim 7, it is characterised in that: described mouth
Formulation is granule, tablet, capsule, mixture.
9. according to the preparation side of a kind of compositions with fat-reducing and immunoregulation effect described in any one of claim 1 ~ 8
Method, it is characterised in that comprise the steps:
(1) raw material is weighed by weight；
(2) Radix Astragali, Fructus Lycii, Radix Codonopsis, Ganoderma and people are participated in the water heating extraction at least 2 times of at least 10 times amount, extracts every time
Time is at least 2 hours, united extraction liquid, filters, obtains filtrate；
(3) step (2) gained filtrate is condensed into thick paste；
(4) step (3) gained thick paste is dried to obtain dry extract；
(5) step (4) gained dry extract is pulverized and sieved, obtain dry extract；
(6) Pollen Pini is sieved, obtain Pollen Pini fine powder；
(7) dextrin of step (5) gained dry extract amount 0.8 ~ 1.5 times amount is weighed, with described dry extract, step (6) gained
Pollen Pini fine powder mix homogeneously；Adding appropriate 85% ethanol is wetting agent soft material；
(8) step (7) gained soft material is sieved granulation, obtain wet granular, wet grain drying, granulate, packaging, obtain granule.
10. a kind of compositions with fat-reducing and immunoregulation effect described in claim 1～8 any one is lost weight in preparation
With the purposes in food, health product or the medicine of immunoregulation effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610729488.0A CN106214844A (en) | 2016-08-26 | 2016-08-26 | A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610729488.0A CN106214844A (en) | 2016-08-26 | 2016-08-26 | A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106214844A true CN106214844A (en) | 2016-12-14 |
Family
ID=57555447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610729488.0A Pending CN106214844A (en) | 2016-08-26 | 2016-08-26 | A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106214844A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107125502A (en) * | 2017-05-11 | 2017-09-05 | 朱晓军 | Five-element's food-conditioning method |
| CN107252110A (en) * | 2017-05-04 | 2017-10-17 | 成都众宜创展商贸有限公司 | It is a kind of to strengthen the preparation method of body immunity and antidepression health food |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264170A (en) * | 2008-04-30 | 2008-09-17 | 于晶 | Tianshen oral liquid with fatigue-resistance and immunoregulation action |
| CN101780136A (en) * | 2010-03-17 | 2010-07-21 | 上海大学 | Medicine and food dual-purpose traditional Chinese medicine composition with anti-tumor activity and immunoregulation effect and application thereof |
-
2016
- 2016-08-26 CN CN201610729488.0A patent/CN106214844A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264170A (en) * | 2008-04-30 | 2008-09-17 | 于晶 | Tianshen oral liquid with fatigue-resistance and immunoregulation action |
| CN101780136A (en) * | 2010-03-17 | 2010-07-21 | 上海大学 | Medicine and food dual-purpose traditional Chinese medicine composition with anti-tumor activity and immunoregulation effect and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 百草益寿补气养血: "百草益寿茶有什么作用和功效？", 《HTTP://BLOG.SINA.COM.CN/S/BLOG_15B9A2F360102WZ7H.HTML》 * |
| 蔡东联等: "《女性美容营养与饮食：吃出美丽来》", 30 November 2000, 上海科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107252110A (en) * | 2017-05-04 | 2017-10-17 | 成都众宜创展商贸有限公司 | It is a kind of to strengthen the preparation method of body immunity and antidepression health food |
| CN107125502A (en) * | 2017-05-11 | 2017-09-05 | 朱晓军 | Five-element's food-conditioning method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100363022C (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN102406163B (en) | Application of traditional Chinese medicine composition in preparation of health food or medicament for preventing and relieving physical fatigue | |
| US9662349B2 (en) | Dietary composition having mixed polysaccharides derived from lucid ganoderma, lycium barbarum and polygonatum sibiricum and method of its preparation | |
| CN103238756A (en) | Compound feed for finishing pigs and preparation method thereof | |
| CN100420448C (en) | Health-care food with function for improving immunity and its prepn. method | |
| CN105434842A (en) | Traditional Chinese medicine composition for strengthening immunity and improving sleep as well as preparation and preparation method thereof | |
| CN101716256B (en) | Preparation used for strengthening immunity | |
| CN109394809A (en) | A kind of Chinese medicine composition and its preparation method and application improving immunity | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN106214844A (en) | A kind of compositions with fat-reducing and immunoregulation effect and preparation method thereof | |
| CN112915181A (en) | Qi-tonifying and vitality-restoring ointment formula and application thereof | |
| CN105535425B (en) | A kind of Chinese medicine composition with strengthen immunity effect and preparation method thereof and purposes | |
| CN108066384A (en) | A kind of Chinese medicine preparation with strengthen immunity and preparation method thereof | |
| CN104644759B (en) | A kind of health protection tea for preventing or/and treating influenza and preparation method thereof | |
| CN106728387B (en) | Compound medicine with function of promoting immunity and preparation method thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN102973725A (en) | Lentinan capsules | |
| CN104258327A (en) | Health granules for boosting immunity and preparation method of health granules | |
| CN104524233B (en) | A kind of BRM for promoting hematopoiesis function to improve immunity and its preparation and application | |
| CN102406172B (en) | Health-care food for enhancing immunity and preparation method thereof | |
| CN103230003B (en) | Health food with immunity boosting function and preparation method thereof | |
| CN1207030C (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN102631492B (en) | Chinese medicinal composition for improving immunity and resisting fatigue | |
| CN101537079B (en) | Pharmaceutical composition or health-care product for improving sleeping and delaying senility and preparation method thereof | |
| CN105168582A (en) | Traditional Chinese medicine composite for treating child cold and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |